Skip to Content


In the US, Lanreotide (lanreotide systemic) is a member of the drug class somatostatin and somatostatin analogs and is used to treat Acromegaly, Carcinoid Syndrome and Neuroendocrine Carcinoma.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antineoplastic agent

Growth hormone release inhibiting hormone analogue (analogue of somatostatin)

Chemical Names

3-(2-Naphtyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-treoninamid, cycl.(2-7)-disulfid (IUPAC)

3-(2-Naphtyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-treoninamide, cyclic (2->7)-disulfide (WHO)

L-treoninamide, 3-(2-naphtalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2->7)-disulfide

Foreign Names

  • Lanreotidum (Latin)
  • Lanreotid (German)
  • Lanréotide (French)
  • Lanreotida (Spanish)

Generic Names

  • Lanreotide (OS: BAN)
  • Lanréotide (OS: DCF)
  • Angiopeptin (IS)
  • BIM 23014 (IS)
  • BN 52030 (IS)
  • DC 13-116 (IS)
  • UNII-0G3DE8943Y (IS)
  • Lanreotide Acetate (OS: USAN, JAN)
  • BIM 23014C (IS)
  • UNII-IEU56G3J9C (IS)

Brand Names

  • Somatuline
    Gen, Turkey; Ipsen, Poland; Ipsen, Slovakia
  • Somatuline LA
    Ipsen Biopharm, United Kingdom
  • Somatuline LP
    Beaufour Ipsen, Tunisia; Ipsen Beaufour, Lebanon
  • Somatuline PR
    Ipsen, Poland; Ipsen, Taiwan
  • Ipstyl
    2care4, Norway; Farmagon, Norway; Ipsen, Denmark; Ipsen, Italy; Ipsen, Norway; Orifarm, Norway
  • Somatulina
    Ipsen, Spain; Ipsen, Portugal
  • Somatulina Autogel
    Ipsen, Spain
  • Somatuline
    A. Menarini, Thailand; Beaufour Ipsen, China; EMD Serono, Canada; Eureco-Pharma, Netherlands; Fisher Farma, Netherlands; Future Health Pharma, Switzerland; Ipsen, Australia; Ipsen, Belgium; Ipsen, Estonia; Ipsen, Finland; Ipsen, Georgia; Ipsen, Greece; Ipsen, Hungary; Ipsen, Ireland; Ipsen, Israel; Ipsen, Latvia; Ipsen, Netherlands; Ipsen, Slovakia; Ipsen Biopharm, United Kingdom; Ipsen Pharma, Austria; Ipsen Pharma, Czech Republic; Ipsen Pharma, Germany; Ipsen Pharma, Lithuania; Ipsen Pharma, Romania; Ipsen Pharma, Serbia; Medcor, Netherlands; PharmaSwiss, Croatia (Hrvatska); Sanofi Aventis, Chile; Sanofi-Aventis, Argentina; Sanofi-Aventis, Colombia; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, Mexico; Teijin Pharma, Japan
  • Somatuline Depot
    Ipsen, United States
  • Somatuline LA
    Ipsen, Australia; Ipsen Biopharm, United Kingdom
  • Somatuline LP
    Ipsen Pharma, France
  • Somatuline PR
    Beaufour Ipsen, Hong Kong; Beaufour Ipsen, Romania; Ipsen, Estonia; Ipsen, Hungary; Ipsen, Netherlands; Ipsen Pharma, Lithuania
  • Somatuline retard
    Ipsen Pharma, Austria
  • Somatuline
    Ipsen Pharma, Austria


BANBritish Approved Name
DCFDénomination Commune Française
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.